NCT04989283 2023-09-26
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
National Cancer Institute (NCI)
Emory University
University of Texas Southwestern Medical Center
Eli Lilly and Company
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Fox Chase Cancer Center
Spectrum Pharmaceuticals, Inc